Orgenesis Total Assets 2013-2021 | ORGS

Orgenesis total assets from 2013 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Orgenesis Annual Total Assets
(Millions of US $)
2020 $78
2019 $92
2018 $74
2018 $75
2017 $40
2016 $33
2015 $39
2014 $2
2013 $0
2012 $0
2012 $0
2011 $0
Orgenesis Quarterly Total Assets
(Millions of US $)
2021-09-30 $65
2021-06-30 $76
2021-03-31 $82
2020-12-31 $78
2020-09-30 $111
2020-06-30 $119
2020-03-31 $127
2019-12-31 $92
2019-09-30 $80
2019-06-30 $85
2019-03-31 $85
2018-12-31 $74
2018-11-30 $75
2018-08-31 $69
2018-05-31 $47
2018-02-28 $42
2017-11-30 $40
2017-08-31 $37
2017-05-31 $36
2017-03-31 $0
2017-02-28 $0
2016-12-31 $33
2016-11-30 $33
2016-09-30 $0
2016-08-31 $0
2016-06-30 $0
2016-05-31 $0
2015-12-31 $39
2014-12-31 $2
2013-12-31 $0
2012-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.076B $0.008B
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.142B 7.97
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.170B 20.61
Biohaven Pharmaceutical Holding (BHVN) United States $6.566B 0.00
Arcus Biosciences (RCUS) United States $3.079B 0.00
Emergent Biosolutions (EBS) United States $2.259B 8.12
Myovant Sciences (MYOV) United Kingdom $1.408B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.382B 0.00
Zymeworks (ZYME) Canada $0.848B 0.00
SQZ Biotechnologies (SQZ) United States $0.318B 0.00
Ambrx Biopharma (AMAM) United States $0.306B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90